Complain about a product or service

Vioxx Critic To Publish Report

January 3, 2005
Merck Pharmaceutical is bracing for some bad news at the start of the new year. A leading critic of its arthritis pain reliever Vioxx is preparing to publish a paper about the now-removed drug, and he's not expected to have many kind things to say about it.

Related Stories • Pfizer Pays Record $2.3 Billion Settlement Over Illegal Marketing Charges • Court Snuffs Vioxx Suit • Pfizer Pays $894 Million to Settle NSAID Claims • Researchers Claim Vioxx Safety Study Was Actually Marketing Plan • First Vioxx Judgment Overturned On Appeal • Merck Agrees to Pay $58 Million to Settle Vioxx Claims • Researchers Claim Merck Cooked Vioxx Data • Common Pain Relievers May Boost Muscle Mass • More Painkillers Can Cause More Pain • Merck Caves, Agrees To $4.85 Billion Vioxx Settlement • New York Sues Vioxx Maker over Drug’s Risks • Merck Wins Vioxx Case In Illinois • Judge Rules Out Vioxx "Super" Class Action • FDA Critic Blasts Merck's Vioxx Replacement • Merck Loses New Orleans Vioxx Case • Merck Wins Latest Vioxx Suit • Vioxx Study Authors Backtrack On Claim • Older Painkillers May Increase Heart Attack Risk • More about Vioxx --- Other NSAIDs • Bextra • Celebrex • Dangers of Other Vioxx-Type Drugs • Vioxx Alternatives • Aleve Ingredient Seen as Health Risk

Food and Drug Administration safety expert David Graham is putting on paper many of the things he said in person to a Senate committee in November, when he charged that as many as 138,000 people have have suffered heart attacks or strokes because they had been taking Vioxx.

Graham said his estimate of the death toll caused by Vioxx has not changed since his Senate testimony.

Two months earlier Merck abruptly pulled its popular prescription pain killer off the market, saying studies had shown a link between the drug, a COX-2 inhibitor, and increased risk of heart attack and stroke.

The appearance of a paper by Graham, a harsh critic of safety procedures used by major drug companies, is expected to further fan the flames of bad publicity and lawsuits facing Merck. The drug company already faces several class action lawsuits filed by former Vioxx users.

Graham's paper was to have been published in the prestigious British medical journal Lancet, giving it even higher impact. But Graham told Forbes its publication by Lancet was delayed due to conflicts with officials at FDA.

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.

Share		Follow us on Twitter.

Back to the top |